Japan's Dainippon Sees Success In Phase III Trials For Schizophrenia Drug
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma of Japan reported Phase III success with its lurasidone drug to treat schizophrenia. The company said that as a result, it plans to apply to the U.S. FDA early next year for approval. The drug is part of the atypical antipsychotics class of drug that works by blocking brain serotonin receptors. The final-stage trial was conducted on patients who had schizophrenia for an average of 13 years and had been hospitalized recently. (Click here for more
You may also be interested in...
Japanese Dainippon Sumitomo Pharma To Acquire Sepracor For $2.6 Billion
The share price of Sepracor surged by over 25 percent to a high of $22.80 before trading was halted mid-day on Sept. 2, amid speculation of an imminent takeover by Japan's Dainippon Sumitomo Pharma
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.